TOMI Reaffirms $12M Revenue Guidance for 2026 Amid Defense and Nuclear Expansion
Event summary
- TOMI reaffirmed its $12M revenue guidance for fiscal 2026, driven by a 100%+ YoY sales increase and $6.2M in booked orders.
- $8.6M of TOMI’s $35M sales pipeline is in advanced stages, with key projects involving major medical and defense clients.
- The Carbonium Core merger remains on track for H2 2026, targeting nuclear-grade graphite production for next-gen reactors.
- TOMI expanded EU regulatory approvals to nine countries and deepened partnerships in Germany, UK, Netherlands, and Israel.
The big picture
TOMI’s reaffirmed guidance reflects strong momentum in defense, biosafety, and international markets. The Carbonium merger signals a strategic shift into nuclear materials, aligning with global decarbonization trends. Success hinges on executing high-value projects and integrating the acquisition.
What we're watching
- Merger Integration
- Whether the Carbonium Core merger will successfully pivot TOMI into the high-growth nuclear materials sector.
- Defense Sector Growth
- The pace at which defense contracts in Korea, Canada, and the U.S. translate into long-term revenue streams.
- Regulatory Expansion
- How EU approvals and partnerships will impact TOMI’s international sales trajectory beyond 2026.
Related topics